Alzheimer’s Journal Disciplines Researchers for Perceived Ethics Violation Over Aducanumab Paper
An Alzheimer’s Association-owned science journal has disciplined three researchers after they tweeted a link to their pre-print study that offers a negative assessment of Biogen’s investigational Alzheimer’s treatment, aducanumab.
The journal, Alzheimer’s & Dementia, reportedly informed the scientists in late December that they had committed an ethics violation and placed them on a two-year publishing probation. The Alzheimer’s Association, which has been lobbying the FDA to approve aducanumab as an Alzheimer’s treatment, claims it had nothing to do with the journal’s action.
The FDA is expected to issue a decision on Biogen’s Biologics License Application for aducanumab by June 7.